Anti-human papillomavirus therapeutics: facts & future.
Even after 25 years of establishing Human Papillomavirus (HPV) as the causative agent for cervical cancer, effective treatment of HPV infection still unavailable. Comprehensive efforts especially for targeting HPV infection have been made only in recent years. Conventional physical ablation of HPV-induced lesions such as cryo-therapy, photo-therapy, LEEP, laser cone-biopsy and localized radiotherapy are shown to be effective to some extent in treating localized lesions where the removal of diseased tissue is associated with removal of transforming keratinocytes harboring HPV. Apart from currently available prophylactic vaccines which prevent the viral entry and should be given prior to viral exposure, several attempts are being made to develop therapeutic vaccines that could treat prevailing HPV infection. In addition, immunomodulators like interferons and imiquimod that have been shown to elicit cytokine milieu to enhance host immune response against HPV infection. Also, antiviral approaches such as RNA interference (RNAi) nucleotide analogs, antioxidants and herbal derivatives have shown effective therapeutic potential against HPV infection. These leads are being tested in pre-clinical and clinical studies. Present article provides a brief overview of conventional therapies for HPV-associated diseases. Potential of non-ablative anti-HPV treatment modalities that could prove useful for either elimination of HPV in early stages of infection when the virus is not integrated into the host cell genome or suppression of the expression of viral oncogenes that dys-regulate the host cell cycle following transformation is discussed.
Bharti
Alok C
AC
Division of Molecular Oncology, Institute of Cytology & Preventive Oncology (ICMR), Noida, India.
Shukla
Shirish
S
Mahata
Sutapa
S
Hedau
Suresh
S
Das
Bhudev C
BC
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000472:pathogenicity; D030361:Papillomavirus Infections / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000494:pharmacology; D010778:Photochemotherapy; D008517:Phytotherapy; D034622:RNA Interference; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000628:therapy / Q000821:virology
D000970:Antineoplastic Agents; D053918:Papillomavirus Vaccines